These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 7791962)
1. [125I]-BQ3020, a potent ETB-selective agonist, displays species differences in its binding characteristics. Nambi P; Pullen M Neuropeptides; 1995 Mar; 28(3):191-6. PubMed ID: 7791962 [TBL] [Abstract][Full Text] [Related]
2. Species differences in the binding characteristics of [125I]IRL-1620, a potent agonist specific for endothelin-B receptors. Nambi P; Pullen M; Spielman W J Pharmacol Exp Ther; 1994 Jan; 268(1):202-7. PubMed ID: 8301559 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of the rat cerebellar endothelin B (ETB) receptor using the novel agonist radioligand [125I]BQ3020. Jarvis MF; Assal AA; Gessner G Brain Res; 1994 Nov; 665(1):33-8. PubMed ID: 7882015 [TBL] [Abstract][Full Text] [Related]
4. Characterization of [125I]-endothelin-1 and [125I]-BQ3020 binding to rat cerebellar endothelin receptors. Widdowson PS; Kirk CN Br J Pharmacol; 1996 Aug; 118(8):2126-30. PubMed ID: 8864551 [TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a novel endothelin receptor that binds both ETA- and ETB-selective ligands. Nambi P; Pullen M; Kincaid J; Nuthulaganti P; Aiyar N; Brooks DP; Gellai M; Kumar C Mol Pharmacol; 1997 Oct; 52(4):582-9. PubMed ID: 9380020 [TBL] [Abstract][Full Text] [Related]
6. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart. Molenaar P; Kuc RE; Davenport AP Br J Pharmacol; 1992 Nov; 107(3):637-9. PubMed ID: 1472961 [TBL] [Abstract][Full Text] [Related]
7. Correlation between guanine nucleotide effect and reversible binding property of endothelin analogs. Nambi P; Pullen M; Aiyar N Neuropeptides; 1996 Feb; 30(1):109-14. PubMed ID: 8868308 [TBL] [Abstract][Full Text] [Related]
8. [125I]BQ3020, a novel endothelin agonist selective for the endothelinB receptor subtype. Assal AA; Gessner G; Jarvis MF Brain Res Brain Res Protoc; 1997 Feb; 1(1):23-6. PubMed ID: 9385043 [TBL] [Abstract][Full Text] [Related]
9. Endothelin receptors in human coronary artery and aorta. Bacon CR; Davenport AP Br J Pharmacol; 1996 Mar; 117(5):986-92. PubMed ID: 8851522 [TBL] [Abstract][Full Text] [Related]
10. ETA and ETB endothelin receptors in human myometrium characterized by the subtype selective ligands BQ123, BQ3020, FR139317 and PD151242. Bacon CR; Morrison JJ; O'Reilly G; Cameron IT; Davenport AP J Endocrinol; 1995 Jan; 144(1):127-34. PubMed ID: 7891013 [TBL] [Abstract][Full Text] [Related]
11. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart. Peter MG; Davenport AP Br J Pharmacol; 1996 Feb; 117(3):455-462. PubMed ID: 8821534 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the binding of endothelin ETB selective ligands in human and rat heart. Russell FD; Davenport AP Br J Pharmacol; 1996 Oct; 119(4):631-6. PubMed ID: 8904635 [TBL] [Abstract][Full Text] [Related]
13. Identification of ETB receptor subtypes using linear and truncated analogs of ET. Nambi P; Pullen M; Brooks DP; Gellai M Neuropeptides; 1995 Dec; 29(6):331-6. PubMed ID: 8837960 [TBL] [Abstract][Full Text] [Related]
14. Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart. Peter MG; Davenport AP Br J Pharmacol; 1995 Jan; 114(2):297-302. PubMed ID: 7881728 [TBL] [Abstract][Full Text] [Related]
15. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Karet FE; Kuc RE; Davenport AP Kidney Int; 1993 Jul; 44(1):36-42. PubMed ID: 8355464 [TBL] [Abstract][Full Text] [Related]
16. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. Davenport AP; O'Reilly G; Molenaar P; Maguire JJ; Kuc RE; Sharkey A; Bacon CR; Ferro A J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S22-5. PubMed ID: 7509950 [TBL] [Abstract][Full Text] [Related]
17. Identification of a novel endothelin receptor in Xenopus laevis liver. Nambi P; Pullen M; Kumar C Neuropeptides; 1994 Mar; 26(3):181-5. PubMed ID: 8208363 [TBL] [Abstract][Full Text] [Related]
18. Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors. Nambi P; Pullen M; Wu HL; Lee D; Saunders D; Heys R; Aiyar N; Leber J; Elliott J; Brooks D; Ohlstein E; Ruffolo R J Pharmacol Exp Ther; 1996 Jun; 277(3):1567-71. PubMed ID: 8667224 [TBL] [Abstract][Full Text] [Related]
19. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions. Chin MH; Cioffi CL; Garay M; Neale RF; Shetty SS; DelGrande D; Mugrage B; Sills MA; Lipson KE J Pharmacol Exp Ther; 1996 Jan; 276(1):74-83. PubMed ID: 8558459 [TBL] [Abstract][Full Text] [Related]
20. [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature. Davenport AP; Kuc RE; Hoskins SL; Karet FE; Fitzgerald F Br J Pharmacol; 1994 Dec; 113(4):1303-10. PubMed ID: 7534185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]